SG11202100706UA - Composition containing influenza vaccine - Google Patents

Composition containing influenza vaccine

Info

Publication number
SG11202100706UA
SG11202100706UA SG11202100706UA SG11202100706UA SG11202100706UA SG 11202100706U A SG11202100706U A SG 11202100706UA SG 11202100706U A SG11202100706U A SG 11202100706UA SG 11202100706U A SG11202100706U A SG 11202100706UA SG 11202100706U A SG11202100706U A SG 11202100706UA
Authority
SG
Singapore
Prior art keywords
composition containing
influenza vaccine
containing influenza
vaccine
composition
Prior art date
Application number
SG11202100706UA
Inventor
Yoshimasa Takahashi
Yu Adachi
Manabu Ato
Akihisa Fukushima
Original Assignee
Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan As Represented By Director General Of Nat Institute Of Infectious Diseases, Sumitomo Dainippon Pharma Co Ltd filed Critical Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
Publication of SG11202100706UA publication Critical patent/SG11202100706UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202100706UA 2018-07-23 2019-07-22 Composition containing influenza vaccine SG11202100706UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018138001 2018-07-23
JP2019038976 2019-03-04
PCT/JP2019/028674 WO2020022272A1 (en) 2018-07-23 2019-07-22 Composition containing influenza vaccine

Publications (1)

Publication Number Publication Date
SG11202100706UA true SG11202100706UA (en) 2021-03-30

Family

ID=69181520

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100706UA SG11202100706UA (en) 2018-07-23 2019-07-22 Composition containing influenza vaccine

Country Status (13)

Country Link
US (1) US20210353737A1 (en)
EP (1) EP3827842A4 (en)
JP (1) JP7395461B2 (en)
KR (1) KR20210034614A (en)
CN (1) CN112839673A (en)
AU (1) AU2019311965A1 (en)
BR (1) BR112021001188A8 (en)
CA (1) CA3107409A1 (en)
IL (1) IL280332A (en)
MX (1) MX2021000951A (en)
SG (1) SG11202100706UA (en)
TW (1) TW202011986A (en)
WO (1) WO2020022272A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7403733B2 (en) 2017-09-04 2023-12-25 国立感染症研究所長 Method for manufacturing influenza HA split vaccine
EA202191786A1 (en) * 2018-12-26 2021-11-03 Сумитомо Дайниппон Фарма Ко., Лтд. PREPARATION CONTAINING VACCINE ADJUVANT
JPWO2020179797A1 (en) * 2019-03-04 2020-09-10
JP2023520376A (en) * 2020-03-27 2023-05-17 ピーエイティエイチ Malaria transmission blocking vaccine
EP4171630A1 (en) * 2020-06-29 2023-05-03 Path Pre-erythrocytic malaria vaccines

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
ES2232871T3 (en) 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited NEW DERIVATIVES OF PURINA.
ES2205573T3 (en) 1997-11-28 2004-05-01 Sumitomo Pharmaceuticals Company, Limited NEW HETEROCICLIC COMPOUNDS.
EP1110951B1 (en) 1998-08-27 2004-05-19 Sumitomo Pharmaceuticals Company, Limited Pyrimidine derivatives
JP4331944B2 (en) 2001-04-17 2009-09-16 大日本住友製薬株式会社 New adenine derivatives
AU2004252409A1 (en) 2003-04-10 2005-01-06 3M Innovative Properties Company Methods and compositions for enhancing immune response
CA2535338C (en) 2003-08-14 2013-05-28 3M Innovative Properties Company Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
JP4689338B2 (en) 2005-04-26 2011-05-25 キヤノン株式会社 Sheet processing apparatus and image forming apparatus
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
ES2374455T3 (en) 2006-02-17 2012-02-16 Pfizer Limited DERIVATIVES OF 3-DEAZAPURINZA AS MODULATORS OF TLR7.
CL2008000496A1 (en) 2007-02-19 2008-09-22 Smithkline Beecham Corp COMPOUNDS DERIVED FROM PURINA; PROCEDURE FOR PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT INFECTIOUS DISEASES, CANCER, ALLERGIES AND OTHER INFLAMMATORY AFFECTIONS.
DK2132209T3 (en) 2007-03-19 2014-04-14 Astrazeneca Ab 9-SUBSTITUTED 8-OXO ADENINE COMPOUNDS AS MODULATORS OF TLR7 (TOLL-LIKE RECEPTOR 7)
JP5329444B2 (en) 2007-03-19 2013-10-30 アストラゼネカ・アクチエボラーグ 9-Substituted-8-oxo-adenine compounds as TOLL-like receptor (TLR7) modulators
US8044056B2 (en) * 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
TW200902018A (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
JP5400763B2 (en) 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ Imidazoquinolines with immunomodulatory properties
US7968544B2 (en) 2007-06-29 2011-06-28 Gilead Sciences, Inc. Modulators of toll-like receptor 7
PE20091236A1 (en) 2007-11-22 2009-09-16 Astrazeneca Ab PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7
EP2324025A1 (en) 2008-08-11 2011-05-25 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
UA103195C2 (en) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
SG193149A1 (en) 2008-08-11 2013-09-30 Glaxosmithkline Llc Novel adenine derivatives
PT2341933T (en) 2008-10-24 2018-02-13 Glaxosmithkline Biologicals Sa Lipidated imidazoquinoline derivatives
ES2623794T3 (en) 2008-12-09 2017-07-12 Gilead Sciences, Inc. Intermediates for the preparation of toll receptor modulators
KR20110117705A (en) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 Toll-like receptor modulators and treatment of diseases
WO2010133885A1 (en) 2009-05-21 2010-11-25 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
EA023536B1 (en) 2009-08-07 2016-06-30 Глаксосмитклайн Байолоджикалс Са Oxoadenine derivatives conjugated with phospho- or phosphonolipids
US20130202629A1 (en) 2010-04-30 2013-08-08 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
WO2012024284A1 (en) 2010-08-17 2012-02-23 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
US8895570B2 (en) 2010-12-17 2014-11-25 Astrazeneca Ab Purine derivatives
RS60191B1 (en) 2011-04-08 2020-06-30 Janssen Sciences Ireland Unlimited Co Pyrimidine derivatives for the treatment of viral infections
SI2709989T1 (en) 2011-05-18 2018-04-30 Janssen Sciences Ireland Uc Quinazoline derivatives for the treatment of viral infections and further diseases
WO2013173256A2 (en) 2012-05-16 2013-11-21 Kj Biosciences, Llc New and improved influenza vaccines
TWI619704B (en) 2012-05-18 2018-04-01 大日本住友製藥股份有限公司 Carboxylic acid compounds
EP2925729B1 (en) 2012-11-16 2017-10-18 Janssen Sciences Ireland UC Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
KR20140118682A (en) 2013-03-29 2014-10-08 (주)셀트리온 Composition comprising two or more influenza A viruses neutralizing binding molecules
CN107427571A (en) * 2014-12-31 2017-12-01 ***合众国,由健康及人类服务部部长代表 Novel multivalent vaccine based on nano particle
EP3355933B1 (en) 2015-09-29 2020-05-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
US10632192B2 (en) 2015-10-07 2020-04-28 Sumitomo Dainippon Pharma Co., Ltd. Pyrimidine compounds and their use as vaccine adjuvants

Also Published As

Publication number Publication date
CA3107409A1 (en) 2020-01-30
BR112021001188A2 (en) 2021-04-27
KR20210034614A (en) 2021-03-30
AU2019311965A1 (en) 2021-02-25
MX2021000951A (en) 2021-06-23
CN112839673A (en) 2021-05-25
JP7395461B2 (en) 2023-12-11
IL280332A (en) 2021-03-25
TW202011986A (en) 2020-04-01
BR112021001188A8 (en) 2022-12-06
WO2020022272A1 (en) 2020-01-30
EP3827842A1 (en) 2021-06-02
EP3827842A4 (en) 2022-04-20
JPWO2020022272A1 (en) 2021-08-05
US20210353737A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
ZA201801035B (en) Vaccine compositions
EP3538146A4 (en) Influenza vaccine
SG11202010821TA (en) Vaccine composition
IL280332A (en) Composition containing influenza vaccine
ZA201904505B (en) Universal influenza vaccine compositions
GB201802339D0 (en) Immunogenic composition
HK1259146A1 (en) Methods and compositions for influenza vaccination
GB201707189D0 (en) Novel formulations
GB201707188D0 (en) Novel formulations
EP3305328A4 (en) Non-gelatin vaccine protectant composition and live attenuated influenza vaccine
SG11202009147UA (en) Vaccine compositions
GB201910794D0 (en) Vaccine
GB2562241B (en) Vaccine compositions
ZA201802565B (en) New adjuvant and vaccine composition containing the same
PL3595617T3 (en) Nail enamel composition
GB201703529D0 (en) Vaccine composition
GB201707187D0 (en) Novel formulations
EP3710051A4 (en) Vaccine compositions
EP3677276A4 (en) Vaccine composition
GB201811382D0 (en) Vaccine
SG11202002933TA (en) Compositions for booster vaccination against dengu
GB201703483D0 (en) Dental compositions
GB201807376D0 (en) HMCV Vaccine Composition
GB201807378D0 (en) Vaccine composition
GB201809541D0 (en) Vaccine compositions